Tag Directory / PUBLICHEALTH     showing 321–340 of 502   RSS



Boehringer wins accelerated approval for first-line use of lung cancer drug

Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated

AI Summary: Regulators accelerated approval of Boehringer Ingelheim’s lung cancer therapy for first‑line use, leveraging a priority review mechanism that sped the timeline. The label expansion places the drug into earlier treatment settings, reflecting promising data and the efficiency (and occasional controversy) of voucher‑assisted regulatory pathways.

5 months / medicalxpress

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily

6 months / oncodaily




Patient dies in MacroGenics' cancer study, FDA puts trial on hold

Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...

AI Summary: Regulators have imposed a partial hold on a Phase 2 gynecologic cancer trial after multiple serious adverse events, including one patient death and additional safety incidents. The pause mandates review of trial protocols and safety monitoring before enrollment can resume, highlighting the inherent risks when experimental therapies meet human biology.




UHS posts 11.5% operating margin in 2025 as net income jumps 30%

Andrew Cass / beckershospitalreview - King of Prussia, Pa.-based Universal Health Services recorded a net income of $1.5 billion in 2025, up from $1.1 billion in 2024, according to its Feb. 25 financial report. Eight things to know: 1. The for-profit system reported an operating income of $2 …

AI Summary: Universal Health Services reported robust 2025 financial results and outlined an optimistic 2026 outlook, driven by acute and behavioral health operations. Leadership flagged growth targets for admissions and behavioral services even as staffing and regulatory pressures persist — the usual blend of confidence and contingency planning.

6 months / fiercehealthcare




Cancer blood test fails to catch disease earlier in major study

medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.

AI Summary: A large trial evaluating GRAIL’s multi‑cancer blood screening test failed to meet its primary goal of earlier cancer detection. The disappointing result casts doubt on the test’s clinical utility for population screening, sparks debate over marketing and clinical use, and prompts calls for clearer evidence before widespread adoption.

5 months / oncodaily

5 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / medicalxpress




More Research, Less Cancer: £250m raised to transform the future of cancer research

Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…

AI Summary: The More Research Less Cancer campaign has reached a £250 million fundraising milestone to accelerate cancer research, support translational projects, and expand patient-focused initiatives. Donor momentum will underwrite discovery science and clinical translation, giving researchers more runway to turn promising lab findings into treatments patients might actually see.

5 months / oncodaily

5 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / medicalxpress

6 months / oncodaily

6 months / oncodaily

6 months / esmo

6 months / oncodaily

6 months / oncodaily

6 months / nature

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / medicalxpress

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / medicalxpress

6 months / nature

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / medicalxpress

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / bbc




FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026

oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]

AI Summary: The FDA released draft guidance creating a regulatory pathway to speed individualized and N-of-1 cell and gene therapies for ultra‑rare diseases. The framework clarifies evidence expectations, manufacturing and safety-monitoring options, and trial design flexibility to help get bespoke treatments from bench to bedside faster — no miracles promised, just fewer bureaucratic speed bumps.

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily




ChatGPT Health performance in a structured test of triage recommendations

Ashwin Ramaswamy / nature - Nature Medicine, Published online: 23 February 2026; doi:10.1038/s41591-026-04297-7A stress test of ChatGPT Health triage revealed missed high-risk emergencies and inconsistent activation of suicide-crisis safeguards, raising safety concerns for consumer-…

AI Summary: A structured, independent evaluation found that ChatGPT Health—an AI tool offering consumer triage and health guidance—missed or misclassified high-risk cases and gave inconsistent advice. Researchers and clinicians raised safety concerns about relying on the system for urgent medical decision-making, calling for tighter oversight and validation before broad public deployment.

5 months / medicalxpress

5 months / oncodaily

5 months / oncodaily

6 months / medicalxpress

6 months / medicalxpress

6 months / livescience

6 months / oncodaily

6 months / medicalxpress




Brain injury is almost ten times more common in unhoused people. Addressing it is key to reducing homelessness

medicalxpress - On any given night, 60,000 people in Canada will go to sleep homeless. Research estimates that more than half of them have had a brain injury at one point in their lives, most of them being injured before becoming homeless. An estimated 22.5% live with mo…

AI Summary: Research indicates people experiencing homelessness suffer brain injuries at dramatically higher rates—approaching a tenfold increase—compared with housed populations. Advocates and clinicians call for routine screening, accessible neurorehabilitation, trauma-informed services and coordinated housing support to address long-term disability and reduce homelessness cycles. The findings argue treating injuries, not just symptoms, yields better social and health outcomes.

6 months / bbc

6 months / medicalxpress

6 months / medicalxpress




‘You’re not the Lone Ranger’ anymore: Medical education evolves for team-based care

Paige Twenter / beckershospitalreview - As U.S. healthcare increasingly adopts team-based care, medical schools are working to prepare students for future care delivery models, according to a Feb. 18 article from the Association of American Medical Colleges. Team-based care, or a coordinated ba…

AI Summary: A multi‑agent AI system called DeepRare has proven it can outpace physicians in head‑to‑head rare‑disease diagnosis tests, promising to shorten the notorious “diagnostic odyssey.” Industry leaders tout this as a practical diagnostic aid, while experts caution about validation, integration into clinical workflows and equity in access before it replaces any human judgment.

6 months / medicalxpress

6 months / oncodaily




A novel C. diff vaccine shows promise

Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…

AI Summary: Researchers at Vanderbilt have reported a novel experimental vaccine that prevents Clostridioides difficile infection and reduces recurrence in early studies, demonstrating strong protective immune responses. The work offers a much‑needed alternative to antibiotics and recurrent‑infection management, though larger clinical trials will be required to confirm safety, durability and real‑world impact.

6 months / medicalxpress




Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks

Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.

AI Summary: A Nature Medicine study presents plasma p‑tau217 “clocks” that estimate when symptomatic Alzheimer’s disease is likely to begin, offering a blood-based forecast years before cognitive decline appears. The test could reshape trial enrollment, early intervention timing and patient counseling—validation and access hurdles remain, but at least worried boomers get a calendar to dread.

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress

6 months / discovermagazine




CDC confirms 910 measles cases in 2026; South Carolina remains hardest hit

Paige Twenter / beckershospitalreview - Six weeks into 2026, the CDC has confirmed 910 measles cases. If the pace of transmission continues, this year could far outpace the 2,280 cases detected across the U.S. in 2025, as 2026’s total is already 40% of 2025’s. The hardest-hit state is South Car…

AI Summary: The CDC has confirmed a nationwide uptick in measles cases, tallying hundreds of infections and triggering local public-health responses. Hotspots include a large South Carolina outbreak, an over‑40‑case cluster at a Florida college and a Los Angeles County case involving visits to LAX eateries while infectious. Officials urge vaccination and vigilance.

6 months / medicalxpress

6 months / medicalxpress

6 months / medicalxpress




Mysterious Virus Hiding Inside Common Gut Bacterium Linked to Colorectal Cancer

discovermagazine - A previously unknown virus may be the key to assessing the risk of colorectal cancer and improving diagnosis.

AI Summary: Scientists have identified a novel virus residing within a common gut bacterium that appears associated with colorectal cancer, offering a potential new biomarker for risk and diagnosis. Early work suggests this viral–microbe interaction could reshape screening strategies if subsequent studies confirm causation and clinical utility.

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / nature

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / medicalxpress

6 months / oncodaily

6 months / kffhealthnews

6 months / discovermagazine

6 months / medicalxpress




Mississippi hospital system closes all clinics after ransomware attack

abcnews - A ransomware attack has forced the University of Mississippi Medical Center to close clinics and cancel elective procedures for a second day

AI Summary: A cyberattack forced the University of Mississippi Medical Center to take Epic and other systems offline, leading to canceled appointments, closed clinics and an FBI response. Officials say investigations are ongoing while clinicians scramble to deliver care without their usual electronic lifelines.

6 months / abcnews




Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50%

Frank Vinluan / medcitynews - Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for pre…

AI Summary: Grail’s multi‑cancer Galleri blood screen failed to meet the primary endpoint in a large UK trial, undermining claims of near-term population screening utility and prompting a sharp market reaction. Researchers noted signals that merit further study, but the study outcome raises fresh doubts about broad clinical deployment and reimbursement prospects.

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily

6 months / oncodaily




'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice

livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.

AI Summary: Scientists reported a nasal-spray vaccine that protected mice against a range of respiratory viruses, bacteria and even a common allergen, a tantalizing step toward a universal respiratory vaccine. The animal data look promising, but human trials are essential before anyone ditches annual shots for a single spritz and a prayer.

6 months / livescience

6 months / medicalxpress

6 months / bbc




Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment

discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.

AI Summary: A comparative genomics study finds the household cat shares key cancer mutations with humans across several tumor types, offering a practical animal model for understanding tumor biology and testing therapies. Researchers suggest these feline-human parallels could accelerate translational oncology for both species, turning a once-dismissed pet anecdote into useful science.

6 months / bbc

6 months / discovermagazine

6 months / medicalxpress




Ultramarathon Running Could Rapidly Age and Breakdown Red Blood Cells

discovermagazine - Learn more about the impact ultramarathon running has on red blood cells and how it may do more harm than good for the body.

AI Summary: New research shows that extreme ultramarathon efforts cause rapid red blood cell breakdown and markers of accelerated cellular aging, potentially impairing oxygen delivery and recovery. Scientists warn that while endurance feats make great headlines, the physiological cost to blood health may be substantial and warrants monitoring in athletes.

6 months / discovermagazine

6 months / newscientist

6 months / medicalxpress




Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV

medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…

AI Summary: Researchers mined the blood of pediatricians — occupationally exposed to many childhood viruses — to isolate highly potent antibodies, then combined them into a cocktail that neutralizes respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Preclinical results show strong neutralization and protection, offering a promising prophylactic or therapeutic option for infants and at-risk adults.

6 months / medicalxpress

6 months / newscientist




FDA formalizes one pivotal trial policy via NEJM perspective

Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...

AI Summary: The FDA has moved to make a single pivotal trial the new default for drug approvals, abandoning the long-standing two-study standard to speed access and ease OTC transitions. The policy, outlined by agency leaders and discussed in a NEJM perspective, raises questions about evidence thresholds and downstream safety monitoring. Welcome to faster approvals — now let's hope that lone study behaves.

6 months / medicalxpress




Back to Top


PUBLICHEALTH Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try CDC, Health Disparities, Food Safety, None and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.